Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration

Neuroscience Letters

Volumn 548, Issue , 2013, Pages 170-175

  Dardiotis, Efthimios ^a   Panayiotou, Elena ^a   Feldman, Marianne L ^a   Hadjisavvas, Andreas ^a   Malas, Stavros ^a   Vonta, Ilia ^b   Hadjigeorgiou, Georgios ^c   Kyriakou, Kyriakos ^a   Kyriakides, Theodoros ^a  

^a CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

^b NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

^c INSTITUTE OF HUMAN PERFORMANCE AND REHABILITATION   (Greece)

Author keywords

Amyotrophic lateral sclerosis; G93ASOD1 transgenic mouse model; Melatonin; Neuroprotection; Oxidative stress

Indexed keywords

4 HYDROXYNONENAL; COPPER ZINC SUPEROXIDE DISMUTASE; MELATONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GENE EXPRESSION; HISTOCHEMISTRY; HISTOPATHOLOGY; MALE; MOTONEURON; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPINAL CORD; UPREGULATION; WESTERN BLOTTING;

ALS; AMYOTROPHIC LATERAL SCLEROSIS; G93ASOD1 TRANSGENIC MOUSE MODEL; MELATONIN; NEUROPROTECTION; OXIDATIVE STRESS; SOD1; SUPEROXIDE DISMUTASE GENE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTIOXIDANTS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; INFUSIONS, PARENTERAL; MELATONIN; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; SUPEROXIDE DISMUTASE; TREATMENT OUTCOME;

EID: 84880136528     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.05.058     Document Type: Article

References (20)

1. Beni S.M., Kohen R., Reiter R.J., Tan D.X., Shohami E. Melatonin-induced neuroprotection after closed head injury is associated with increased brain antioxidants and attenuated late-phase activation of NF-kappaB and AP-1. FASEB Journal 2004, 18:149-151.
2. Cleveland D.W., Rothstein J.D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nature Reviews Neuroscience 2001, 2:806-819.
3. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., Chen W., Zhai P., Sufit R.L., Siddique T. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994, 264:1772-1775.
4. Jacob S., Poeggeler B., Weishaupt J.H., Siren A.L., Hardeland R., Bahr M., Ehrenreich H. Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients. Journal of Pineal Research 2002, 33:186-187.
5. Kiernan M.C., Vucic S., Cheah B.C., Turner M.R., Eisen A., Hardiman O., Burrell J.R., Zoing M.C. Amyotrophic lateral sclerosis. Lancet 2011, 377:942-955.
6. Kim J., Kim T.Y., Hwang J.J., Lee J.Y., Shin J.H., Gwag B.J., Koh J.Y. Accumulation of labile zinc in neurons and astrocytes in the spinal cords of G93A SOD-1 transgenic mice. Neurobiology of Disease 2009, 34:221-229.
7. Korkmaz A., Reiter R.J., Topal T., Manchester L.C., Oter S., Tan D.X. Melatonin: an established antioxidant worthy of use in clinical trials. Molecular Medicine 2009, 15:43-50.
8. Lee E.J., Lee M.Y., Chen H.Y., Hsu Y.S., Wu T.S., Chen S.T., Chang G.L. Melatonin attenuates gray and white matter damage in a mouse model of transient focal cerebral ischemia. Journal of Pineal Research 2005, 38:42-52.
9. Liu J.B., Tang T.S., Yang H.L., Xiao D.S. Antioxidation of melatonin against spinal cord injury in rats. Chinese Medical Journal 2004, 117:571-575.
10. Micale V., Arezzi A., Rampello L., Drago F. Melatonin affects the immobility time of rats in the forced swim test: the role of serotonin neurotransmission. European Neuropsychopharmacology 2006, 16:538-545.
11. Ozdemir D., Tugyan K., Uysal N., Sonmez U., Sonmez A., Acikgoz O., Ozdemir N., Duman M., Ozkan H. Protective effect of melatonin against head trauma-induced hippocampal damage and spatial memory deficits in immature rats. Neuroscience Letters 2005, 385:234-239.
12. Pei Z., Pang S.F., Cheung R.T. Administration of melatonin after onset of ischemia reduces the volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. Stroke 2003, 34:770-775.
13. Perluigi M., Fai Poon H., Hensley K., Pierce W.M., Klein J.B., Calabrese V., De Marco C., Butterfield D.A. Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice-a model of familial amyotrophic lateral sclerosis. Free Radical Biology and Medicine 2005, 38:960-968.
14. Reiter R.J., Tan D.X., Manchester L.C., Lopez-Burillo S., Sainz R.M., Mayo J.C. Melatonin: detoxification of oxygen and nitrogen-based toxic reactants. Advances in Experimental Medicine and Biology 2003, 527:539-548.
15. Rogerio F., Teixeira S.A., de Rezende A.C., de Sa R.C., de Souza Queiroz L., De Nucci G., Muscara M.N., Langone F. Superoxide dismutase isoforms 1 and 2 in lumbar spinal cord of neonatal rats after sciatic nerve transection and melatonin treatment. Brain Research. Developmental Brain Research 2005, 154:217-225.
16. Seo J.S., Baek I.S., Leem Y.H., Kim T.K., Cho Y., Lee S.M., Park Y.H., Han P.L. SK-PC-B70M alleviates neurologic symptoms in G93A-SOD1 amyotrophic lateral sclerosis mice. Brain Research 2011, 1368:299-307.
17. Shokouhi G., Tubbs R.S., Shoja M.M., Hadidchi S., Ghorbanihaghjo A., Roshangar L., Farahani R.M., Mesgari M., Oakes W.J. Neuroprotective effects of high-dose vs low-dose melatonin after blunt sciatic nerve injury. Childs Nervous System 2008, 24:111-117.
18. Tai S.H., Hung Y.C., Lee E.J., Lee A.C., Chen T.Y., Shen C.C., Chen H.Y., Lee M.Y., Huang S.Y., Wu T.S. Melatonin protects against transient focal cerebral ischemia in both reproductively active and estrogen-deficient female rats: the impact of circulating estrogen on its hormetic dose-response. Journal of Pineal Research 2011, 50:292-303.
19. Tapias V., Cannon J.R., Greenamyre J.T. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model. Journal of Neuroscience Research 2010, 88:420-427.
20. Weishaupt J.H., Bartels C., Polking E., Dietrich J., Rohde G., Poeggeler B., Mertens N., Sperling S., Bohn M., Huther G., Schneider A., Bach A., Siren A.L., Hardeland R., Bahr M., Nave K.A., Ehrenreich H. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. Journal of Pineal Research 2006, 41:313-323.